|

Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients

RECRUITINGPhase 3Sponsored by University of California, San Diego
Actively Recruiting
PhasePhase 3
SponsorUniversity of California, San Diego
Started2022-01-01
Est. completion2027-08-31
Eligibility
Age0 Years – 50 Years
Healthy vol.Accepted
Locations4 sites

Summary

The purpose of this study is to evaluate the effectiveness of a multi-component intervention to improve young cancer survivors' engagement in goal-concordant oncofertility care, concurrently with observing and gathering information on how the intervention is implemented. The investigators hypothesize that implementation of the intervention will result in increased young cancer survivors' engagement in goal-concordant oncofertility care.

Eligibility

Age: 0 Years – 50 YearsHealthy volunteers accepted
Inclusion Criteria:

* Newly diagnosed cancer or cancer relapse
* Primary language English or Spanish
* Receiving oncology care at participating clinical sites
* Ages 0 to 42 years if female
* Ages 0 to 50 years if male

Exclusion Criteria:

* Non-melanoma skin cancer, because primary treatment is excision with no infertility risk
* Metastatic/Stage IV non-thyroid solid tumors, because of poor prognosis

Conditions2

CancerFertility Preservation

Locations4 sites

City of Hope
Duarte, California, 91010-3000
Saro Armenian, DO, MPH626-471-7320sarmenian@coh.org
Cancer Resource Center of the Desert
El Centro, California, 92243
University of California San Diego
La Jolla, California, 92093
H. Irene Su, MD, MSCE858-822-5986hisu@health.ucsd.edu
Rady Children's Hospital San Diego
San Diego, California, 92123
Paula Aristizabal, MD, MAS858-966-5811paristizabal@rchsd.org

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.